NCT00263692 - Comparison of GSK Biologicals' DTaP-IPV Candidate Vaccine to DTaP and IPV Separately Administered Vaccines in Terms of Immune Response and Safety | Biotech Hunter

Enrollment

401

Participants

Timeline

Start Date

November 30, 2002

Primary Completion Date

September 30, 2004

Study Completion Date

September 30, 2004

Conditions

DiphtheriaAcellular PertussisTetanus

Interventions

BIOLOGICAL

Prophylaxis: Diphtheria, tetanus, pertussis, poliovirus type 1, type 2 and type 3

Trial Locations (15)

GSK Investigational Site, Stony Brook

GSK Investigational Site, Endwell

GSK Investigational Site, Pittsburgh

GSK Investigational Site, Mechanicsville

GSK Investigational Site, Marietta

GSK Investigational Site, Woodstock

GSK Investigational Site, Chicago

GSK Investigational Site, New Orleans

GSK Investigational Site, Ruston

GSK Investigational Site, Jonesboro

GSK Investigational Site, Torrance

GSK Investigational Site, Fountain Valley

GSK Investigational Site, Oakland

GSK Investigational Site, Berlin

GSK Investigational Site, Whitehouse Station